NCT05562791

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).

Conditions

• Bladder Cancer

Interventions

Type	Name	Description
DRUG	[68Ga]PSMA	68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
DIAGNOSTIC_TEST	PET/CT imaging	68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

Timeline

• Start date: 2022-09-28
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2022-10-03
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study